Inhibition of hedgehog signaling ameliorates hepatic inflammation in mice with nonalcoholic fatty liver disease

Hepatology

Volumn 63, Issue 4, 2016, Pages 1155-1169

  Kwon, Hyunjoo ^a   Song, Kyoungsub ^a   Han, Chang ^a   Chen, Weina ^a   Wang, Ying ^a,b   Dash, Srikanta ^a   Lim, Kyu ^c   Wu, Tong ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c Chungnam National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1BETA; INTERLEUKIN 6; LED 225; MONOCYTE CHEMOTACTIC PROTEIN 1; OSTEOPONTIN; PROTEIN INHIBITOR; RECOMBINANT PROTEIN; SONIC HEDGEHOG PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VISMODEGIB; ANILIDE; PYRIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CELL ACTIVATION; DRUG EFFECT; GENE ACTIVATION; GENETIC TRANSFECTION; GLUCOSE INTOLERANCE; HEPATITIS; HEPATOBILIARY SYSTEM INFLAMMATION; IMMUNOHISTOCHEMISTRY; KNOCKOUT MOUSE; LIMIT OF QUANTITATION; LIPID DIET; LIPID STORAGE; LIVER CELL; LIVER INJURY; MACROPHAGE; MACROPHAGE ACTIVATION; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PARACRINE SIGNALING; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; ANIMAL; CELL CULTURE; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECTS; INFLAMMATION; METABOLISM; NEEDLE BIOPSY; PATHOLOGY; PHYSIOLOGY; RANDOMIZATION; SENSITIVITY AND SPECIFICITY;

ANILIDES; ANIMALS; BIOPSY, NEEDLE; CELLS, CULTURED; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; HEDGEHOG PROTEINS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MACROPHAGES; MICE; MICE, KNOCKOUT; NON-ALCOHOLIC FATTY LIVER DISEASE; PYRIDINES; RANDOM ALLOCATION; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION;

EID: 84951760732     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.28289     Document Type: Article

References (41)

1. Michelotti GA, Machado MV, Diehl AM. NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol 2013;10:656-665.
2. Guy CD, Suzuki A, Zdanowicz M, Abdelmalek MF, Burchette J, Unalp A, et al. Hedgehog pathway activation parallels histologic severity of injury and fibrosis in human nonalcoholic fatty liver disease. Hepatology 2012;55:1711-1721.
3. Wree A, Broderick L, Canbay A, Hoffman HM, Feldstein AE. From NAFLD to NASH to cirrhosis-new insights into disease mechanisms. Nat Rev Gastroenterol Hepatol 2013;10:627-636.
4. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001;120:1183-1192.
5. Kojima H, Sakurai S, Uemura M, Fukui H, Morimoto H, Tamagawa Y. Mitochondrial abnormality and oxidative stress in nonalcoholic steatohepatitis. Alcohol Clin Exp Res 2007;31:S61-S66.
6. Sun B, Karin M. Obesity, inflammation, and liver cancer. J Hepatol 2012;56:704-713.
7. Omenetti A, Choi S, Michelotti G, Diehl AM. Hedgehog signaling in the liver. J Hepatol 2011;54:366-373.
8. Swiderska-Syn M, Suzuki A, Guy CD, Schwimmer JB, Abdelmalek MF, Lavine JE, et al. Hedgehog pathway and pediatric nonalcoholic fatty liver disease. Hepatology 2013;57:1814-1825.
9. Cai Y, Zheng H, Gong W, Che Y, Jiang B. The role of hedgehog signaling pathway in liver regeneration. Hepatogastroenterology 2011;58:2071-2076.
10. Michelotti GA, Xie G, Swiderska M, Choi SS, Karaca G, Kruger L, et al. Smoothened is a master regulator of adult liver repair. J Clin Invest 2013;123:2380-2394.
11. Briscoe J, Therond PP. The mechanisms of Hedgehog signalling and its roles in development and disease. Nat Rev Mol Cell Biol 2013;14:416-429.
12. Varjosalo M, Taipale J. Hedgehog: functions and mechanisms. Genes Dev 2008;22:2454-2472.
13. Rangwala F, Guy CD, Lu J, Suzuki A, Burchette JL, Abdelmalek MF, et al. Increased production of sonic hedgehog by ballooned hepatocytes. J Pathol 2011;224:401-410.
14. Jung Y, Witek RP, Syn WK, Choi SS, Omenetti A, Premont R, et al. Signals from dying hepatocytes trigger growth of liver progenitors. Gut 2010;59:655-665.
15. Choi SS, Omenetti A, Witek RP, Moylan CA, Syn WK, Jung Y, et al. Hedgehog pathway activation and epithelial-to-mesenchymal transitions during myofibroblastic transformation of rat hepatic cells in culture and cirrhosis. Am J Physiol Gastrointest Liver Physiol 2009;297:G1093-G1106.
16. Hirsova P, Ibrahim SH, Bronk SF, Yagita H, Gores GJ. Vismodegib suppresses TRAIL-mediated liver injury in a mouse model of nonalcoholic steatohepatitis. PLoS One 2013;8:e70599.
17. Omenetti A, Porrello A, Jung Y, Yang L, Popov Y, Choi SS, et al. Hedgehog signaling regulates epithelial-mesenchymal transition during biliary fibrosis in rodents and humans. J Clin Invest 2008;118:3331-3342.
18. Zhao L, Yu Y, Deng C. Protein and mRNA expression of Shh, Smo and Gli1 and inhibition by cyclopamine in hepatocytes of rats with chronic fluorosis. Toxicol Lett 2014;225:318-324.
19. Ramaiah SK, Rittling S. Pathophysiological role of osteopontin in hepatic inflammation, toxicity, and cancer. Toxicol Sci 2008;103:4-13.
20. Nagoshi S. Osteopontin: versatile modulator of liver diseases. Hepatol Res 2014;44:22-30.
21. Patouraux S, Bonnafous S, Voican CS, Anty R, Saint-Paul MC, Rosenthal-Allieri MA, et al. The osteopontin level in liver, adipose tissue and serum is correlated with fibrosis in patients with alcoholic liver disease. PLoS One 2012;7:e35612.
22. Coombes JD, Swiderska-Syn M, Dolle L, Reid D, Eksteen B, Claridge L, et al. Osteopontin neutralisation abrogates the liver progenitor cell response and fibrogenesis in mice. Gut 2015;64:1120-1131.
23. Syn WK, Choi SS, Liaskou E, Karaca GF, Agboola KM, Oo YH, et al. Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis. Hepatology 2011;53:106-115.
24. Machado MV, Cortez-Pinto H. Osteopontin: a missing link between hedgehog signaling and fibrosis in nonalcoholic steatohepatitis. Hepatology 2011;53:382-384.
25. Rulifson IC, Karnik SK, Heiser PW, ten Berge D, Chen H, Gu X, et al. Wnt signaling regulates pancreatic beta cell proliferation. Proc Natl Acad Sci USA 2007;104:6247-6252.
26. Han C, Bowen WC, Michalopoulos GK, Wu T. Alpha-1 adrenergic receptor transactivates signal transducer and activator of transcription-3 (Stat3) through activation of Src and epidermal growth factor receptor (EGFR) in hepatocytes. J Cell Physiol 2008;216:486-497.
27. Han C, Bowen WC, Li G, Demetris AJ, Michalopoulos GK, Wu T. Cytosolic phospholipase A2alpha and peroxisome proliferator-activated receptor gamma signaling pathway counteracts transforming growth factor beta-mediated inhibition of primary and transformed hepatocyte growth. Hepatology 2010;52:644-655.
28. Kumashiro N, Erion DM, Zhang D, Kahn M, Beddow SA, Chu X, et al. Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. Proc Natl Acad Sci USA 2011;108:16381-16385.
29. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010;52:1836-1846.
30. Joshi-Barve S, Barve SS, Amancherla K, Gobejishvili L, Hill D, Cave M, et al. Palmitic acid induces production of proinflammatory cytokine interleukin-8 from hepatocytes. Hepatology 2007;46:823-830.
31. Feldstein AE, Werneburg NW, Canbay A, Guicciardi ME, Bronk SF, Rydzewski R, et al. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology 2004;40:185-194.
32. Bertola A, Deveaux V, Bonnafous S, Rousseau D, Anty R, Wakkach A, et al. Elevated expression of osteopontin may be related to adipose tissue macrophage accumulation and liver steatosis in morbid obesity. Diabetes 2009;58:125-133.
33. Yoon JW, Kita Y, Frank DJ, Majewski RR, Konicek BA, Nobrega MA, et al. Gene expression profiling leads to identification of GLI1-binding elements in target genes and a role for multiple downstream pathways in GLI1-induced cell transformation. J Biol Chem 2002;277:5548-5555.
34. Razumilava N, Gradilone SA, Smoot RL, Mertens JC, Bronk SF, Sirica AE, et al. Non-canonical Hedgehog signaling contributes to chemotaxis in cholangiocarcinoma. J Hepatol 2014;60:599-605.
35. Landsman L, Parent A, Hebrok M. Elevated Hedgehog/Gli signaling causes beta-cell dedifferentiation in mice. Proc Natl Acad Sci USA 2011;108:17010-17015.
36. Day CP. From fat to inflammation. Gastroenterology 2006;130:207-210.
37. Wang X, Lopategi A, Ge X, Lu Y, Kitamura N, Urtasun R, et al. Osteopontin induces ductular reaction contributing to liver fibrosis. Gut 2014;63:1805-1818.
38. Leung TM, Wang X, Kitamura N, Fiel MI, Nieto N. Osteopontin delays resolution of liver fibrosis. Lab Invest 2013;93:1082-1089.
39. Syn WK, Agboola KM, Swiderska M, Michelotti GA, Liaskou E, Pang H, et al. NKT-associated hedgehog and osteopontin drive fibrogenesis in non-alcoholic fatty liver disease. Gut 2012;61:1323-1329.
40. Sahai A, Malladi P, Melin-Aldana H, Green RM, Whitington PF. Upregulation of osteopontin expression is involved in the development of nonalcoholic steatohepatitis in a dietary murine model. Am J Physiol Gastrointest Liver Physiol 2004;287:G264-G273.
41. Musso G, Paschetta E, Gambino R, Cassader M, Molinaro F. Interactions among bone, liver, and adipose tissue predisposing to diabesity and fatty liver. Trends Mol Med 2013;19:522-535.